Clinical Trial Update: Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma [Phase 2]

View source ↗

Summary

Phase II safety and efficacy study of Panzem NCD in patients with recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Panzem NCD

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Recurrent Glioblastoma Multiforme | Phase 2 | Status: COMPLETED